Project Grant R21AI187757

Award Date 7/15/25
Completion Date 6/30/27
Dollars Obligated $424K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Lexington, KY 40526, USA
Similar Awards
This $435,875 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of California, Merced to interrogate the role of the transcriptional regulator NFKBID in humoral immunity against the parasite Toxoplasma gondii. The research aims to define how NFKBID-deficient T follicular helper cells impact B cell antibody responses, and examine the contribution of NFKBID-dependent...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $227,018 to the University of California, Irvine (UCI) from May 1, 2025 to April 30, 2027. The funding supports research to determine the role of microglia, brain-resident immune cells, in defending against Toxoplasma gondii infection in the context of HIV/AIDS-associated immune deficiency. The key objectives...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $563,513 to Arizona State University to conduct research on the patterning, growth, and maturation of the cortical microtubules in the Toxoplasma parasite. The research aims to explore the initiation of microtubule patterning, their growth and maturation, and to reveal the molecular basis for divergence of cytoskeletal structures in...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $408,865 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Vermont & State Agricultural College. The grant supports the development of new tools to study how the protozoan parasite Toxoplasma gondii delivers its "rhoptry effector" proteins into host cells during the invasion process. The goals are to: 1) Develop an assay to test whether the rhoptry...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 - Allergy and Infectious Diseases Research, will support research to investigate the genetic mechanisms that determine host susceptibility to low virulence strains of the Toxoplasma gondii parasite in mice. The $269,054 award, effective November 8, 2024 through October 31, 2026, will enable researchers at the University of California, Merced to leverage the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $214,742 to Texas A&M University to research mechanisms of Toxoplasma gondii vertical transmission and placental barrier crossing. The researchers aim to identify and characterize key T. gondii proteins, such as TgMIF, that enable the parasite to infect the fetus by crossing the placental barrier. They will use...
This $423,500.00 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at the University of Utah to investigate the role of invariant natural killer T (iNKT) cells in shaping the immune response to Plasmodium infection, which can lead to the severe neurological condition of cerebral malaria. The research aims to define how the T cell receptor (TCR) signaling properties of different iNKT cell...
This Project Grant award, totaling $902,964.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to evaluate mechanisms that restrain or enhance alveolar macrophage (AM) responses to Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis, with the goal of understanding the regulation of early events during MTB infection. The key...
This $617,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to delineate the molecular function and contributions to species-specific infection biology of putative glycosyltransferase "cytotoxin" proteins in Chlamydia bacteria. The University of Kentucky Research Foundation, the awardee, has applied genetic and biochemical approaches to investigate...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $520,809 in funding to Rosalind Franklin University of Medicine & Science over the period from September 5, 2024 to August 31, 2029. The overarching goal of this research project is to investigate the role of TAM receptors in modulating the humoral immune response against parasitic infections, such as malaria....

This federal Project Grant award, totaling $423,500.00, was provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to The University of Kentucky Research Foundation. The grant will fund research to determine the protective roles of the CD180 and NOD1 molecules in activating the immune response against Toxoplasma gondii infection in the brain. Specifically, the research aims to investigate how these molecules expressed in microglia and macrophages can activate the production of key immune factors, IFN-γ and TNF-α, to promptly detect and inhibit the growth of Toxoplasma tachyzoites and prevent reactivation of chronic cerebral toxoplasmosis. The research, to be conducted from July 2025 through June 2027, seeks to advance the understanding of innate and adaptive immune mechanisms that can protect against this parasitic infection of the central nervous system.

Generated 8/5/25, 4:55 AM